Bone Biologics regains Nasdaq minimum bid price compliance; stock continues listing

Bone Biologics Corp

Received Nasdaq notice confirming compliance with minimum bid price rule (Rule 5550(a)(2)).
Compliance met on Jan 4, 2024 after 10 consecutive trading days with closing bid price over $1.00.
Stock will continue on Nasdaq Capital Market under discretionary panel monitor until June 28, 2024.
Previously notified of deficiency on Sep 27, 2023 for failing to maintain $1.00 closing bid for 30 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.